ArticleWorld journal of urology2026
Efficacy of the optilume® drug-coated balloon for recurrent urethral stricture after prior urethroplasty: a 12-month multicenter follow-up study.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecurrent urethral stricture following urethroplasty remains a clinical challenge. This study aimed to evaluate the efficacy and safety of the Optilume® paclitaxel drug-coated balloon (DCB) in patients with recurrent anterior urethral strictures after prior urethroplasty.
methodsThis multicentre retrospective study included 25 male patients (mean age 60.6 ± 18.25 years) treated at two German centres between January 2021 and October 2025. The Optilume® DCB (30 Fr, 5 cm) was deployed under cystoscopic guidance and inflated to 10 atm for 7 min. The primary endpoint was functional success, defined as absence of obstructive symptoms and freedom from re-intervention at 12 months. Secondary endpoints included changes in International Prostate Symptom Score (IPSS), IPSS quality of life (IPSS-QoL), and post-void residual (PVR) urine.
resultsOf the 25 treated patients, 23 had completed 12-month follow-up and were evaluable for the primary endpoint; functional success was achieved in 19 of these 23 patients (83%). Kaplan-Meier analysis demonstrated a 1-year freedom-from-re-intervention rate of 75.4% (95% CI 60.0-94.7%). Mean IPSS improved from 23.6 ± 7.25 to 16.8 ± 9.84 (p = 0.001; Cohen's d = 0.73), while IPSS-QoL improved from 4.6 ± 0.92 to 3.0 ± 1.85 (p < 0.001; Cohen's d = 0.79). PVR showed a non-significant reduction (93.8 to 71.0 mL; p = 0.137). No major complications or cases of urinary incontinence were observed. Median follow-up was 13.4 months (IQR 9.9-20.6).
conclusionThe Optilume® DCB represents an effective and minimally invasive salvage treatment for recurrent anterior urethral stricture after urethroplasty, providing durable functional improvement and low retreatment rates at 12 months.
Indexed as
Identifiers
42240867What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.